Clinical Trial

IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a randomized, controlled, double-blind, multicenter, phase III clinical study to evaluate the efficacy of IMM0306 (Amulirafusp Alfa)in combination with lenalidomide versus placebo in combination with lenalidomide in patients with Relapsed/Refractory Follicular lymphoma. Primary endpoints are Complete Remission Rate (CRR) and Progression-Free Survival (PFS).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-12.
Trial Details
NCT Number NCT07355283
Lead Sponsor ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Conditions Relapsed/Refractory Follicular Lymphoma
Enrollment 198 participants
Start Date 2026-02
Primary Completion 2028-07 (estimated)
Study Completion 2030-10 (estimated)
Updated on ClinicalTrials.gov 2026-01-27